Trials / Completed
CompletedNCT06834789
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-151586 | Intramuscular injection |
| DRUG | OnabotulinumtoxinA | Intramuscular injection |
| DRUG | Placebo | Intramuscular injection |
Timeline
- Start date
- 2025-02-18
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
- First posted
- 2025-02-19
- Last updated
- 2025-11-17
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06834789. Inclusion in this directory is not an endorsement.